2018
Resection of retroperitoneal sarcoma en‐bloc with inferior vena cava: 20 year outcomes of a single institution
Blair AB, Reames BN, Singh J, Gani F, Overton HN, Beaulieu RJ, Lum YW, Black JH, Johnston FM, Ahuja N. Resection of retroperitoneal sarcoma en‐bloc with inferior vena cava: 20 year outcomes of a single institution. Journal Of Surgical Oncology 2018, 118: 127-137. PMID: 29878363, PMCID: PMC6220674, DOI: 10.1002/jso.25096.Peer-Reviewed Original Research
2016
Predictors of improved survival for patients with retroperitoneal sarcoma
Giuliano K, Nagarajan N, Canner JK, Wolfgang CL, Bivalacqua T, Terezakis S, Herman J, Schneider EB, Ahuja N. Predictors of improved survival for patients with retroperitoneal sarcoma. Surgery 2016, 160: 1628-1635. PMID: 27495850, DOI: 10.1016/j.surg.2016.05.041.Peer-Reviewed Original ResearchConceptsRetroperitoneal sarcomaMultivariable survival analysisSurvival analysisRetroperitoneal sarcoma patientsEnd Results (SEER) databaseOperative resectionImproved survivalLymph nodesSurvival benefitDistant metastasisHistologic typeResults databaseSarcoma patientsRare tumorCancer DatabaseLonger survivalPatientsSarcomaSurvivalParametric survival functionsLocal extensionFurther studiesHigh rateResectionRecurrenceLong‐term outcomes in treatment of retroperitoneal sarcomas: A 15 year single‐institution evaluation of prognostic features
Abdelfatah E, Guzzetta AA, Nagarajan N, Wolfgang CL, Pawlik TM, Choti MA, Schulick R, Montgomery EA, Meyer C, Thornton K, Herman J, Terezakis S, Frassica D, Ahuja N. Long‐term outcomes in treatment of retroperitoneal sarcomas: A 15 year single‐institution evaluation of prognostic features. Journal Of Surgical Oncology 2016, 114: 56-64. PMID: 27076350, PMCID: PMC4917421, DOI: 10.1002/jso.24256.Peer-Reviewed Original ResearchConceptsCompartmental resectionRPS patientsSurgical resectionPrognostic factorsR0/R1 marginsR0/R1 resectionEn bloc surgical resectionBloc surgical resectionCornerstone of therapyMainstay of treatmentFive-year survivalRetrospective chart reviewPresence of metastasesEn bloc resectionExtent of resectionConnective tissue tumorsJohns Hopkins HospitalWarrants further investigationR1 resectionRetroperitoneal sarcomaChart reviewMedian survivalR1 marginsDistal recurrenceLocal recurrenceIs long‐term survival possible after margin‐positive resection of retroperitoneal sarcoma (RPS)?
Klooster B, Rajeev R, Chrabaszcz S, Charlson J, Miura J, Bedi M, Gamblin T, Johnston F, Turaga K. Is long‐term survival possible after margin‐positive resection of retroperitoneal sarcoma (RPS)? Journal Of Surgical Oncology 2016, 113: 823-827. PMID: 27060344, DOI: 10.1002/jso.24232.Peer-Reviewed Original ResearchConceptsLong-term survivalMargin-positive resectionRetroperitoneal sarcomaR2 resectionResection of retroperitoneal sarcomaNational Cancer Database dataBenefit of chemotherapyCox regression modelsShort-term survivalCompare LTPositive resectionR0/R1 resectionMedian survivalResection rateImproved survivalPostoperative yearYounger patientsResectionFollow-upHistological characteristicsPatientsRegression modelsSurvivalChemotherapySarcomaNeoadjuvant radiotherapy for retroperitoneal sarcoma: A systematic review
Cheng H, Miura J, Lalehzari M, Rajeev R, Donahue A, Bedi M, Gamblin T, Turaga K, Johnston F. Neoadjuvant radiotherapy for retroperitoneal sarcoma: A systematic review. Journal Of Surgical Oncology 2016, 113: 628-634. PMID: 26990903, DOI: 10.1002/jso.24221.Peer-Reviewed Original ResearchConceptsExternal beam radiation therapyRetroperitoneal sarcomaMedian 5-year OSPatients treated with IMRTTreatment of retroperitoneal sarcomasMeta-analysis of observational studiesBeam radiation therapyMedian Follow-UpMulti-modality treatmentNCI CTCAENeoadjuvant radiotherapyRandomized Controlled TrialsLRR rateLocal recurrenceNeoadjuvant radiationRadiation therapyHistological subtypesMedian ageTumor differentiationRetrospective studyTreatment regimensFollow-upLocal controlGrade 1Observational study
2015
Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma
Miura J, Charlson J, Gamblin T, Eastwood D, Banerjee A, Johnston F, Turaga K. Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma. European Journal Of Surgical Oncology 2015, 41: 1386-1392. PMID: 26251340, DOI: 10.1016/j.ejso.2015.07.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChemotherapy, AdjuvantCohort StudiesFemaleFibrosarcomaHumansLeiomyosarcomaLiposarcomaLogistic ModelsMaleMiddle AgedNeoplasm GradingNeoplasm StagingProportional Hazards ModelsRadiotherapy, AdjuvantRetroperitoneal NeoplasmsRetrospective StudiesSarcomaSurgical Procedures, OperativeSurvival RateTreatment OutcomeConceptsRetroperitoneal sarcomaOverall survivalRoutine use of chemotherapyMultivariate Cox proportional hazards modelEffective systemic agentsResectable retroperitoneal sarcomaAssess overall survivalNational Cancer DatabaseMultimodal treatment strategiesUse of chemotherapyFactors associated with receiptUndifferentiated pleomorphic sarcomaPropensity scoreReceipt of CTCox proportional hazards modelsImpact of chemotherapyReceipt of chemotherapyLong-term survivalProportional hazards modelMedian OSNeoadjuvant settingSystemic chemotherapyChemotherapy regimensPropensity score matchingResection status
2009
Predictors of Survival After Resection of Retroperitoneal Sarcoma
Nathan H, Raut CP, Thornton K, Herman JM, Ahuja N, Schulick RD, Choti MA, Pawlik TM. Predictors of Survival After Resection of Retroperitoneal Sarcoma. Annals Of Surgery 2009, 250: 970-976. PMID: 19644351, PMCID: PMC3099434, DOI: 10.1097/sla.0b013e3181b25183.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantInfant, NewbornKaplan-Meier EstimateMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPostoperative PeriodPrognosisProportional Hazards ModelsRetroperitoneal NeoplasmsRetrospective StudiesRisk FactorsSarcomaSEER ProgramSurvival RateTime FactorsUnited StatesYoung AdultConceptsPrimary retroperitoneal sarcomaRetroperitoneal sarcomaPredictors of survivalAJCC staging systemTumor sizeStaging systemRPS resectionHistological subtypesCurrent AJCC staging systemPatients Undergoing ResectionDiscriminatory abilityEnd Results (SEER) databaseAmerican Joint CommitteeCancer (AJCC) staging systemLymph node metastasisModerate discriminatory abilityMalignant fibrous histiocytomaProportional hazards modelPoor discriminatory abilityPrevalent histologyUndergoing resectionNode metastasisAJCC stageMultivariable analysisResults database
2008
Management of Retroperitoneal Sarcomas
Hueman MT, Herman JM, Ahuja N. Management of Retroperitoneal Sarcomas. 2008, 88: 583-597. PMID: 18514700, DOI: 10.1016/j.suc.2008.03.002.Peer-Reviewed Original ResearchConceptsRetroperitoneal sarcomaLocal recurrenceMorbidity of therapyDistant metastatic diseaseAggressive surgical approachCurative treatment optionManagement of patientsHigh-grade lesionsMetastatic diseaseSurgical therapyTherapeutic challengeSurgical approachTreatment optionsExtent of invasionDisease controlSarcomaCommon typePatientsRecurrenceTherapyMorbidityLesionsManagementDiseaseDiagnosis
2007
The role of radiation in retroperitoneal sarcomas: a surgical perspective
Pawlik TM, Ahuja N, Herman JM. The role of radiation in retroperitoneal sarcomas: a surgical perspective. Current Opinion In Oncology 2007, 19: 359-366. PMID: 17545800, DOI: 10.1097/cco.0b013e328122d757.Peer-Reviewed Original ResearchConceptsExternal beam radiation therapyBeam radiation therapyIntraoperative radiation therapyLocal recurrence rateRadiation therapyRetroperitoneal sarcomaRecurrence rateAdjuvant external beam radiation therapyLocal recurrence-free survivalPreoperative external beam radiation therapyRadiation-related morbidityRetroperitoneal sarcoma patientsLocal control rateLocal-regional controlPreoperative radiation therapyRecurrence-free survivalTiming of administrationSurgical patientsTumor resectabilitySarcoma patientsTechniques of deliveryControl rateSurgical perspectiveAdditional toxicityRecent studiesLow-grade Fibromyxoid Sarcoma Presenting Clinically as a Primary Ovarian Neoplasm
Winfield HL, De Las Casas LE, Greenfield WW, Santin AD, McKenney JK. Low-grade Fibromyxoid Sarcoma Presenting Clinically as a Primary Ovarian Neoplasm. International Journal Of Gynecological Pathology 2007, 26: 173-176. PMID: 17413985, DOI: 10.1097/01.pgp.0000228145.36807.43.Peer-Reviewed Original ResearchConceptsLow-grade fibromyxoid sarcomaFibromyxoid sarcomaMesenchymal neoplasmsLeft-sided pelvic massDisease 11 monthsLeft ovarian massPrimary ovarian neoplasmsSecondary ovarian involvementMiddle-aged patientsBland spindle cell proliferationLeft hypogastric arteryMalignant mesenchymal neoplasmDeep soft tissuesSpindle cell proliferationRetroperitoneal sarcomaAbdominal painUrinary frequencyHypogastric arteryOvarian involvementSurgical resectionOvarian neoplasmsLeft ureterOvarian massesPelvic massFleshy mass
1985
Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum.
Glenn J, Sindelar W, Kinsella T, Glatstein E, Tepper J, Costa J, Baker A, Sugarbaker P, Brennan M, Seipp C. Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum. Surgery 1985, 97: 316-25. PMID: 3975851.Peer-Reviewed Original ResearchConceptsRandomized studyTwo-year actuarial survival ratesSurvival rateResectable soft tissue sarcomaSevere bone marrow suppressionAggressive multimodality treatmentResectable retroperitoneal sarcomasSevere radiation enteritisActuarial survival rateBone marrow suppressionCyclophosphamide-induced cystitisSoft tissue sarcomasAdjuvant chemotherapyChemotherapy armPostoperative chemotherapyRetroperitoneal sarcomaChemotherapy regimenMajor morbidityMultimodality therapyRadiation enteritisBowel resectionMarrow suppressionMultimodality treatmentMajor complicationsCardiac toxicity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply